Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat
CL Gay, KS James, M Tuyishime… - The Journal of …, 2022 - academic.oup.com
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal
agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS …
agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS …
[HTML][HTML] Identification of a potential miRNA–mRNA regulatory network associated with the prognosis of HBV-ACLF
S Ma, Z Xie, L Zhang, Y Yang, H Jiang… - Frontiers in molecular …, 2021 - frontiersin.org
Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a life-
threatening disease with a high mortality rate; the systemic inflammatory response plays a …
threatening disease with a high mortality rate; the systemic inflammatory response plays a …
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With …
CL Gay, PJ Hanley, SD Falcinelli… - The Journal of …, 2024 - academic.oup.com
Background The histone deacetylase inhibitor vorinostat (VOR) can reverse human
immunodeficiency virus type 1 (HIV-1) latency in vivo and allow T cells to clear infected cells …
immunodeficiency virus type 1 (HIV-1) latency in vivo and allow T cells to clear infected cells …
[HTML][HTML] Hallmarks of retroelement expression in T-cells treated with HDAC inhibitors
A wide spectrum of drugs have been assessed as latency reversal agents (LRA) to
reactivate HIV-1 from cellular reservoirs and aid in viral eradication strategies. Histone …
reactivate HIV-1 from cellular reservoirs and aid in viral eradication strategies. Histone …
Off-Target Effect of Activation of NF-κB by HIV Latency Reversal Agents on Transposable Elements Expression
Many drugs have been evaluated to reactivate HIV-1 from cellular reservoirs, but the off-
target effects of these latency reversal agents (LRA) remain poorly defined. Transposable …
target effects of these latency reversal agents (LRA) remain poorly defined. Transposable …
In vitro Pharmacokinetic/Pharmacodynamic modeling of HIV latency reversal by novel HDAC inhibitors using an automated platform
W Newhard, M Patel, J Cassaday… - … the Science of Drug …, 2021 - journals.sagepub.com
Antiretroviral therapy is able to effectively control but not eradicate HIV infection, which can
persist, leading to the need for lifelong therapy. The existence of latently HIV-infected cells is …
persist, leading to the need for lifelong therapy. The existence of latently HIV-infected cells is …